To help pharmaceutical manufacturers protect temperature-sensitive products during shipment, the Parenteral Drug Association (Bethesda, MD, http://www.pda.org/) has published a guidance document drafted by its Cold Chain Management Task Force and reviewed by technical experts from the industry. Several years in the making, "Technical Report No. 39: Cold Chain Guidance for Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment" discusses how to develop protective packages and systems to provide "thermally controlled transportation" (1). The guidance also aligns with the Center for Drug Evaluation and Research's (Bethesda, MD, http://www.fda.gov/) "General Principles of Process Validation: Component Qualification (CQ), Operating Qualification (OQ), and Performance Qualification (PQ)."
Developing a protective system. The development of a thermally protective system begins with the creation of a functional requirements document and the specification of components such as insulated containers and refrigerants. The functional requirements document includes the critical parameters related to the packaging and transport systems such as the types of vehicle, routes, trip duration, product stability, likely temperature range of exposure, and packaging. The component specification is a detailed description of requirements for features such as material composition, mechanical characteristics, dimensions, printing, storage, sampling, weight, insulation, calibration limits, fragility limits, and shock and vibration limits.
Design testing is the next step. "The outcome of design testing assures a high confidence for successful operational qualification of a specific package or system," the report explains (1).
Then, qualification testing is "performed using the designated configuration to provide assurance that product quality is maintained during transport." Both design and qualification testing results should be documented in a formal report (1).